PMID- 18005037
OWN - NLM
STAT- MEDLINE
DCOM- 20080327
LR  - 20211020
IS  - 1365-2567 (Electronic)
IS  - 0019-2805 (Print)
IS  - 0019-2805 (Linking)
VI  - 123
IP  - 4
DP  - 2008 Apr
TI  - Isolation and characterization of dendritic cells from common marmosets for 
      preclinical cell therapy studies.
PG  - 566-74
AB  - Dendritic cells (DCs) have important functions as modulators of immune responses, 
      and their ability to activate T cells is of great value in cancer immunotherapy. 
      The isolation of DCs from the peripheral blood of rhesus and African green 
      monkeys has been reported, but the immune system in the common marmoset remains 
      poorly characterized, although it offers many potential advantages for 
      preclinical studies. In the present study, we devised methods, based on 
      techniques developed for mouse and human DC preparation, for isolating DCs from 
      three major tissue sources in the common marmoset: bone marrow (BM), spleen and 
      peripheral blood. Each set of separated cells was analysed using the cell surface 
      DC-associated markers CD11c, CD80, CD83, CD86 and human leucocyte antigen 
      (HLA)-DR, all of which are antibodies against human antigens, and the cells were 
      further characterized both functionally and morphologically as antigen-presenting 
      cells. BM proved to be an excellent cell source for the isolation of DCs intended 
      for preclinical studies on cell therapy, for which large quantities of cells are 
      required. In the BM-derived CD11c(+) cell population, cells exhibiting the 
      characteristic features of DCs were enriched, with the typical DC morphology and 
      the abilities to undergo endocytosis, to secrete interleukin (IL)-12, and to 
      stimulate Xenogenic T cells. Moreover, BM-derived DCs produced the neurotrophic 
      factor NT-3, which is also found in murine splenic DCs. These results suggest 
      that BM-derived DCs from the common marmoset may be useful for biological 
      analysis and for preclinical studies on cell therapy for central nervous system 
      diseases and cancer.
FAU - Ohta, Shigeki
AU  - Ohta S
AD  - Neuroimmunology Research Group, Keio University School of Medicine, Tokyo, Japan.
FAU - Ueda, Yoko
AU  - Ueda Y
FAU - Yaguchi, Masae
AU  - Yaguchi M
FAU - Matsuzaki, Yumi
AU  - Matsuzaki Y
FAU - Nakamura, Masaya
AU  - Nakamura M
FAU - Toyama, Yoshiaki
AU  - Toyama Y
FAU - Tanioka, Yoshikuni
AU  - Tanioka Y
FAU - Tamaoki, Norikazu
AU  - Tamaoki N
FAU - Nomura, Tatsuji
AU  - Nomura T
FAU - Okano, Hideyuki
AU  - Okano H
FAU - Kawakami, Yutaka
AU  - Kawakami Y
FAU - Toda, Masahiro
AU  - Toda M
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20071114
PL  - England
TA  - Immunology
JT  - Immunology
JID - 0374672
RN  - 0 (Neurotrophin 3)
RN  - 0 (Recombinant Proteins)
RN  - 207137-56-2 (Interleukin-4)
RN  - 82115-62-6 (Interferon-gamma)
RN  - 83869-56-1 (Granulocyte-Macrophage Colony-Stimulating Factor)
SB  - IM
MH  - Animals
MH  - Bone Marrow Cells/immunology
MH  - Callithrix/*immunology
MH  - Dendritic Cells/*immunology
MH  - Dose-Response Relationship, Immunologic
MH  - Endocytosis/immunology
MH  - Granulocyte-Macrophage Colony-Stimulating Factor/immunology
MH  - Humans
MH  - Interferon-gamma/biosynthesis
MH  - Interleukin-4/immunology
MH  - Lymphocyte Culture Test, Mixed
MH  - Neurotrophin 3/biosynthesis
MH  - Recombinant Proteins/immunology
MH  - Spleen/immunology
MH  - Stem Cells/immunology
PMC - PMC2433308
EDAT- 2007/11/17 09:00
MHDA- 2008/03/28 09:00
PMCR- 2009/04/01
CRDT- 2007/11/17 09:00
PHST- 2007/11/17 09:00 [pubmed]
PHST- 2008/03/28 09:00 [medline]
PHST- 2007/11/17 09:00 [entrez]
PHST- 2009/04/01 00:00 [pmc-release]
AID - IMM2727 [pii]
AID - 10.1111/j.1365-2567.2007.02727.x [doi]
PST - ppublish
SO  - Immunology. 2008 Apr;123(4):566-74. doi: 10.1111/j.1365-2567.2007.02727.x. Epub 
      2007 Nov 14.